Wiener klinische Wochenschrift · 2025
Efficacy and safety of pleural infusion of elemene in the treatment of peritoneal dialysis complicated with pleuroperitoneal communication.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cao Panpan, Su Kangle, Li Fanghua, Wang Xiaoyang, Yuan Wenming, Lu Shan, Liu Dong
Аннотация
PURPOSE: To evaluate the efficacy and safety of elemene pleural instillation in peritoneal dialysis (PD) patients with pleuroperitoneal communication (PPC).
METHODS: This single-center retrospective study enrolled PD patients with PPC who received elemene between October 2020 and January 2022. The diagnosis was confirmed by computed tomography peritoneography (CTP), demonstrating contrast medium in the pleural cavity. Patients received intrapleural elemene (200-400 mg/m2) once or twice weekly. Primary outcomes included treatment efficacy, changes in laboratory parameters, recurrence and safety.
RESULTS: In this study 12 patients were included. After elemene instillation (median follow-up 14.1 months), 10 patients (83.3%) successfully resumed continuous ambulatory peritoneal dialysis. Drug-related adverse events occurred in 9 patients (75.0%): chest pain alone (5, 41.7%) and chest pain with fever (4, 33.3%). All events were CTCAE grade 1 (7, 58.3%) or 2 (2, 16.7%). No significant pretreatment to post-treatment changes were observed in renal function (eGFR), coagulation parameters (PLT, PT, TT, APTT) or dialysis adequacy (Kt/V, Ccr) (all P > 0.05).
CONCLUSION: Elemene pleural instillation appears safe and effective for PD patients with PPC, facilitating resumption of continuous ambulatory peritoneal dialysis.
METHODS: This single-center retrospective study enrolled PD patients with PPC who received elemene between October 2020 and January 2022. The diagnosis was confirmed by computed tomography peritoneography (CTP), demonstrating contrast medium in the pleural cavity. Patients received intrapleural elemene (200-400 mg/m2) once or twice weekly. Primary outcomes included treatment efficacy, changes in laboratory parameters, recurrence and safety.
RESULTS: In this study 12 patients were included. After elemene instillation (median follow-up 14.1 months), 10 patients (83.3%) successfully resumed continuous ambulatory peritoneal dialysis. Drug-related adverse events occurred in 9 patients (75.0%): chest pain alone (5, 41.7%) and chest pain with fever (4, 33.3%). All events were CTCAE grade 1 (7, 58.3%) or 2 (2, 16.7%). No significant pretreatment to post-treatment changes were observed in renal function (eGFR), coagulation parameters (PLT, PT, TT, APTT) or dialysis adequacy (Kt/V, Ccr) (all P > 0.05).
CONCLUSION: Elemene pleural instillation appears safe and effective for PD patients with PPC, facilitating resumption of continuous ambulatory peritoneal dialysis.